Overview

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab